00690.HK
Uni-Bio Science Group Limited
HKSE · Healthcare · Biotechnology · HK
HKD 0.07
+1.54%Year over year
Reported trailing growth
- Revenue
- -6.8%
- EBITDA
- -43.2%
- EBIT
- —
- EPS
- -46.7%
- Free cash flow
- —
- Operating cash flow
- -38.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.0%
- EBITDA
- +24.7%
- EBIT
- +33.2%
- Net income
- +34.3%
- EPS
- +36.8%
- Free cash flow
- +23.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026